Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Witold Ruzyllo

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
American Heart Journal|March 12, 2011
The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy aloneJames E Udelson, Camille A Pearte, Carey D Kimmelstiel, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 22, 2010
PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO studyYves-Laurent Bayard, Heyder Omran, Petr Neuzil, et al.
Circulation. Cardiovascular Interventions|April 17, 2024
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA TrialRadosław Pracoń, John A Spertus, Samuel Broderick, et al.
Lancet (London, England)|August 20, 2013
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trialStephen D Wiviott, Harvey D White, E Magnus Ohman, et al.
The New England Journal of Medicine|November 21, 2013
Edoxaban versus warfarin in patients with atrial fibrillationRobert P Giugliano, Christian T Ruff, Eugene Braunwald, et al.
The New England Journal of Medicine|June 4, 2015
Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesChristopher P Cannon, Michael A Blazing, Robert P Giugliano, et al.
The New England Journal of Medicine|November 16, 2006
Coronary intervention for persistent occlusion after myocardial infarctionJudith S Hochman, Gervasio A Lamas, Christopher E Buller, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
The New England Journal of Medicine|July 26, 2011
Apixaban with antiplatelet therapy after acute coronary syndromeJohn H Alexander, Renato D Lopes, Stefan James, et al.
JAMA Cardiology|February 28, 2019
Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical TrialJudith S Hochman, Harmony R Reynolds, Sripal Bangalore, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
American Heart Journal|March 12, 2011
The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy aloneJames E Udelson, Camille A Pearte, Carey D Kimmelstiel, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 22, 2010
PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO studyYves-Laurent Bayard, Heyder Omran, Petr Neuzil, et al.
Circulation. Cardiovascular Interventions|April 17, 2024
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA TrialRadosław Pracoń, John A Spertus, Samuel Broderick, et al.
Lancet (London, England)|August 20, 2013
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trialStephen D Wiviott, Harvey D White, E Magnus Ohman, et al.
The New England Journal of Medicine|November 21, 2013
Edoxaban versus warfarin in patients with atrial fibrillationRobert P Giugliano, Christian T Ruff, Eugene Braunwald, et al.
The New England Journal of Medicine|June 4, 2015
Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesChristopher P Cannon, Michael A Blazing, Robert P Giugliano, et al.
The New England Journal of Medicine|November 16, 2006
Coronary intervention for persistent occlusion after myocardial infarctionJudith S Hochman, Gervasio A Lamas, Christopher E Buller, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
The New England Journal of Medicine|July 26, 2011
Apixaban with antiplatelet therapy after acute coronary syndromeJohn H Alexander, Renato D Lopes, Stefan James, et al.
JAMA Cardiology|February 28, 2019
Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical TrialJudith S Hochman, Harmony R Reynolds, Sripal Bangalore, et al.
Pageof 11